Physician profile
Larisa Kachowski
NPI 1023214574
$1,389.34
in general payments reported to CMS, 2019-2025
12 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.36 · 2020: $103 · 2021: $205 · 2022: $211 · 2023: $272 · 2024: $243 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.71 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $450.68 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Exact Sciences Corporation | $261.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $111.97 | 2020-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $109.67 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $105.61 | 2023 | |
| Amgen INC. | $84.35 | 2019-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $76.16 | 2024 | Lokelma |
| Esperion Therapeutics, INC. | $70.58 | 2021 | |
| Sumitomo Pharma America, INC. | $40.34 | 2025 | Gemtesa |
| Eisai INC. | $36.14 | 2023-2024 | |
| Boston Scientific Corporation | $22.65 | 2022 | |
| Paratek Pharmaceuticals, INC. | $20.07 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larisa Kachowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.